Status:
COMPLETED
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Intraocular Retinoblastoma
Hearing Loss
Eligibility:
All Genders
3-18 years
Brief Summary
The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
Eligibility Criteria
Inclusion
- Signed informed consent indicating awareness of the investigational nature of the protocol.
- Children with RB aged 3 months and older who are scheduled to receive their first dose of IA carboplatin chemotherapy.
- Retinoblastoma is rarely seen in children over 8 years old, however we will not include an upper age range so as not to exclude any possible participants
Exclusion
- Children with known and documented preexisting hearing loss.
Key Trial Info
Start Date :
March 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 4 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03866460
Start Date
March 6 2019
End Date
November 4 2024
Last Update
November 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065